P
PRME
Prime Medicine
3.24
-0.20-5.81%After Hours: 3.230 -0.01 -0.31%19:48 08/29 EDT
OPEN/PREV CLOSE3.450/3.440
TODAY RANGE3.180-3.480
VOL3.04M
MARKET CAP558.89M
52 WEEK RANGE1.110-5.17
AVG VOL (3M)4.17M
% TURNOVER1.76%
TURNOVER--
P/E (TTM)-2.0703
% RANGE8.72%
EPS(TTM)-1.5650
P/E(FORWARD)-2.7458
P/B7.16
BVPS0.4525
DIVIDEND--
P/S142.73
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP455.42M
SHARES OUTSTANDING172.50M
NEXT EARNINGS11/10-11/14
FREE FLOAT140.56M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·08/13 14:46
Guggenheim Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)
TipRanks·08/12 10:58
Citi Remains a Hold on Prime Medicine, Inc. (PRME)
TipRanks·08/11 10:18
H.C. Wainwright Remains a Hold on Prime Medicine, Inc. (PRME)
TipRanks·08/08 20:55
Chardan Capital Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)
Dow Jones·08/08 20:35
Prime Medicine Price Target Cut to $10.00/Share From $12.00 by Chardan Capital
Dow Jones·08/08 20:35
Prime Medicine Is Maintained at Buy by Chardan Capital
Benzinga·08/08 20:25
Chardan Capital Maintains Buy on Prime Medicine, Lowers Price Target to $10
TipRanks·08/08 05:57
Prime Medicine Reports Q2 2025 Results and Strategic Updates
TipRanks·08/07 16:16
TD Cowen Sticks to Their Buy Rating for Prime Medicine, Inc. (PRME)
Seeking Alpha·08/07 12:29
Prime Medicine GAAP EPS of -$0.41 misses by $0.03, revenue of $1.11M misses by $1.89M
Reuters·08/07 12:11
BRIEF-Prime Medicine, Inc. Q2 Operating Expenses USD 54.492 Million
TipRanks·08/07 12:05
Prime Medicine reports Q2 EPS (41c), consensus (34c)
Dow Jones·08/07 12:02
*Prime Medicine 2Q Loss/Shr 41c >PRME
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.